FDA Times FILSUVEZ Review for Patent Life Extension
Published Date: 12/10/2025
Notice
Summary
The FDA has officially set the review period for FILSUVEZ, a new drug, which helps the company extend its patent protection. This means the drug maker could get extra time to keep their invention exclusive, potentially affecting when generic versions can enter the market. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until early 2026 to speak up.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
FDA Sets FILSUVEZ Review Period
FDA determined the regulatory review period for FILSUVEZ is 1,929 days in total — 935 days in the testing phase and 994 days in the approval phase. Key dates used were: IND effective September 8, 2018 (FDA found; applicant claimed September 5, 2018), NDA initially submitted March 30, 2021, and NDA approval on December 18, 2023. This determination establishes the maximum potential length of a patent extension for this drug and could affect when generic versions can enter the market.
Company Seeks 1,463-Day Patent Extension
The patent applicant for FILSUVEZ is seeking 1,463 days of patent term extension; the FDA's determination sets the maximum potential extension but the U.S. Patent and Trademark Office will apply statutory limitations when calculating the actual extension awarded. If granted, the requested 1,463-day extension would extend the period of exclusivity before generics may enter the market.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2025-22379, Revision of Agency Information Collection Activity Under OMB Review: Secure Flight Program
The TSA is updating how it collects passenger info from airlines to keep flights safe and spot potential threats. This affects U.S. and foreign airlines that share traveler details with the Secure Flight program. You’ve got until January 9, 2026, to share your thoughts, and no big cost changes are expected.
Next: 2025-22381, Foreign-Trade Zone 40; Application for Subzone; Atlantic Veal & Lamb, LLC; Creston and Sterling, Ohio
Atlantic Veal & Lamb, LLC wants to join Foreign-Trade Zone 40 by adding two sites in Creston and Sterling, Ohio. This move could help the company save money on import taxes and speed up their business. Public comments are open until January 20, 2026, so folks have a chance to weigh in before the final decision.